CliffBio
small molecule

ILEVRO

NEPAFENAC

Loss of exclusivityMarch 2032latest FDA-listed patent expiry
CompanyHARROW EYE LLC

Drug detail

Brand nameILEVRO
Active ingredientNEPAFENAC
Strength0.3%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusRX

Listed patents

PatentExpiresType
8921337March 2032product
9662398December 2030product

More from HARROW EYE LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ILEVRO patent cliff — loss of exclusivity March 2032 | CliffBio